Merck & Co., Inc. vs Carparts.Com Inc — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while Carparts.Com Inc trades at $8.64 (market cap $66.42M). The key difference: Merck & Co., Inc. is far larger — about 5288.8× Carparts.Com Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Carparts.Com Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Carparts.Com Inc for 45 Days on average.
| MRK | PRTS | |
|---|---|---|
Market Cap | $351.28B | $66.42M |
Volume | 7,969,665 | 40,287 |
Sector | Health | Consumer Cyclical |
52-Week High | $156.43 | $10.00 |
52-Week Low | $82.49 | $3.88 |
Typical Hold Time | 98 Days | 45 Days |
Enterprise Value | $398.04B | $79.39M |
Dividend Yield | 2.39% | — |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
CarParts.com (PRTS) trades at $8.59, down 1.21% today, with a bullish technical outlook supported by moving averages. The company shows improving earnings momentum with three consecutive quarterly beats, though it remains unprofitable with negative net margins. Revenue has declined from $676M in 2023 to $548M in 2025, but recent quarters suggest stabilization. Analyst sentiment is positive with 60% buy ratings, while technical indicators show neutral oscillators and key support at $8.
The stock presents a turnaround opportunity with improving quarterly performance and strong analyst support, but faces significant fundamental challenges including persistent losses, declining revenue, and negative cash flow from operations. Investors should weigh the bullish technical setup against the company's ongoing profitability struggles and competitive e-commerce landscape.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →